ArticleAdvances in therapy2025
Identifying Parameters Associated with Delayed Diagnosis in Thrombotic Antiphospholipid Syndrome: Data from China Prospective APS Cohort.
Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThe aim of this study was to evaluate the rate of delayed diagnosis in patients with thrombotic antiphospholipid syndrome (tAPS) and explore potential risk factors and prognosis of delayed diagnosis.
methodsThis single-center, prospective study included consecutive patients with tAPS fulfilling the 2006 Sydney Revised Classification Criteria referred to Peking Union Medical College Hospital from June 2012 to September 2022. Patients diagnosed after more than two aPL-related clinical events had occurred were defined as having delayed diagnosis. Logistic regression analysis was used to identify risk factors, and survival analysis was employed to assess prognosis.
resultsA total of 379 patients were enrolled in the study. The mean age was 32.35 ± 13.86 years old, and 221 were female (58.31%), with venous thromboembolism occurring in 174 (45.91%) patients as the first event and arterial thrombosis in 107 (28.23%). Two hundred fifty-four (67.02%) patients had delayed diagnosis. Three high-frequency contributors for delay were obstetric morbidity (39.68%), deep vein thrombosis (26.38%), and thrombocytopenia (19.69%). Multivariate logistic regression indicated that patients with cardiovascular risk factors were more likely to receive delayed diagnosis (odds ratio [OR] = 1.767, 95% confidence interval [CI] 1.129-2.767, P = 0.013). Thrombocytopenia as first events (OR = 2.277, 95% CI 1.159-4.474, P = 0.017) was also a risk factor. Survival analysis showed that APS-related clinical manifestations and thrombotic recurrence were more likely to occur in delayed diagnosis group.
conclusionDelayed diagnosis of tAPS is common, which may lead to poor prognosis. For patients with cardiovascular risk factors and non-criteria manifestations, physicians should be alert to the possibility of APS.
Indexed as
Identifiers
40828348What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.